Brind.

TG Therapeutics signed an SPL agreement with MaxCyte on August 7, 2025.

1 report, 1 independent Updated Aug 7

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

TG Therapeutics MaxCyte (United States)

Keep exploring

The entities involved

TG Therapeutics
a commercial stage biopharmaceutical company
- TG Therapeutics and Aurinia Pharmaceuticals competed in the mid-cap healthcare market.Sat 03:45
MaxCyte (United States)
Biotech company in Rockville, United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 7GlobeNewswireMaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering